brain cancer
Reaction Biology partners with open science company to tackle rare paediatric brain cancer
Contract research organisation (CRO), Reaction Biology, has partnered with an open science drug discovery and development company, M4K Pharma, in the fight against diffuse intrinsic pontine glioma (DIPG) — a rare paediatric brain cancer. Read more
Innovative cancer therapies, like the Datrix novel glioblastoma treatment, should be available on the NHS, notes Jowell
After speaking openly about her brain cancer, the former minister for public health and culture secretary, Tessa Jowell, is now campaigning for cancer patients to have the choice to trial new treatments and stop the ones that aren’t working for them Read more
Glioma treatment receives orphan designation in Europe and the US
Biotech company, VAXIMM, has received orphan designation from the European Commission (EC) and the US Food and Drug Administration (FDA) for its lead product candidate, VXM01, for the treatment of glioma. Read more
Brain cancer vaccine awarded orphan status by FDA
An immunotherapy developed at Roswell Park Cancer Institute has been granted orphan drug status by the US Food and Drug Administration (FDA). Read more
